Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. News
  7. Summary
    ARIX   GB00BD045071

ARIX BIOSCIENCE PLC

(ARIX)
  Report
Delayed Quote. Delayed London Stock Exchange - 07/26 11:35:23 am
174 GBX   -1.42%
12:01pTransaction in own shares
DJ
07/23Transaction in own shares
DJ
07/21Notice of Results
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Harpoon presents updated interim clinical data -2-

06/04/2021 | 10:26am EDT
cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on 
ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple 
myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. 
Harpoon has also developed a proprietary ProTriTAC(TM) platform, which applies a prodrug concept to its TriTAC platform 
to create a therapeutic T cell engager that remains inactive until it reaches the tumor. For additional information 
about Harpoon Therapeutics, please visit www.harpoontx.com. 
Cautionary Note on Forward-looking Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform 
Act of 1995. Words such as "may," "will," "expect," "plan," "potential," "anticipate," "target," "estimate," "intend" 
and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) 
are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon 
Therapeutics' expectations and assumptions as of the date of this press release. Each of these forward-looking 
statements involves risks and uncertainties that could cause Harpoon Therapeutics' clinical development programs, 
future results or performance to differ significantly from those expressed or implied by the forward-looking 
statements. Forward-looking statements contained in this press release include, but are not limited to, statements 
about the anticipated progress, timing, scope and results of preclinical and clinical trials, the association of data 
with potential treatment outcomes, the development and advancement of product candidates, planned additional clinical 
testing and development efforts for its product candidates and the timing thereof, and other statements that are not 
historical fact. Many factors may cause differences between current expectations and actual results, including 
unexpected safety or efficacy data observed during clinical studies, that preliminary data and trends may not be 
predictive of future data or results, may not demonstrate safety or efficacy or lead to regulatory approval by the FDA 
or other regulatory agencies; clinical trial site activation or enrollment rates that are lower than expected, 
unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing 
competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, 
the timing and results of unexpected litigation or other disputes, and the sufficiency of Harpoon Therapeutics' cash 
resources. These and other factors that may cause Harpoon Therapeutics' actual results to differ from those expressed 
or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics' filings with 
the U.S. Securities and Exchange Commission, including under "Risk Factors" in Harpoon Therapeutics' quarterly report 
on Form 10-Q for the quarter ended March 31, 2021 and future filings by Harpoon Therapeutics. Except as required by 
law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect 
any change in expectations, even as new information becomes available. 
Contacts: 
Harpoon Therapeutics, Inc. 
Georgia Erbez 
Chief Financial Officer 
650-443-7400 
media@harpoontx.com 
Westwicke ICR 
Robert H. Uhl 
Managing Director 
858-356-5932 
robert.uhl@westwicke.com 
 
 
=---------------------------------------------------------------------------------------------------------------------- 
ISIN:           GB00BD045071 
Category Code:  MSCH 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:   109497 
EQS News ID:    1204616 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1204616&application_name=news 
 

(END) Dow Jones Newswires

June 04, 2021 10:25 ET (14:25 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
ACTIVATION GROUP HOLDINGS LIMITED -3.61% 0.8 End-of-day quote.3.90%
ARIX BIOSCIENCE PLC -1.42% 174 Delayed Quote.-20.55%
DJ INDUSTRIAL 0.24% 35144.31 Delayed Quote.14.56%
HARPOON THERAPEUTICS, INC. -5.92% 10.81 Delayed Quote.-34.92%
All news about ARIX BIOSCIENCE PLC
12:01pTransaction in own shares
DJ
07/23Transaction in own shares
DJ
07/21Notice of Results
DJ
07/19Transaction in own shares
DJ
07/16Transaction in own shares
DJ
07/14Transaction in own shares
DJ
07/12Transaction in own shares
DJ
07/07Transaction in own shares
DJ
07/06ARIX BIOSCIENCE : Appoints New Managing Director
MT
07/06Team changes
DJ
More news
Financials
Sales 2021 0,50 M 0,69 M 0,69 M
Net income 2021 37,7 M 52,1 M 52,1 M
Net cash 2021 175 M 242 M 242 M
P/E ratio 2021 6,02x
Yield 2021 -
Capitalization 219 M 303 M 303 M
EV / Sales 2021 87,8x
EV / Sales 2022 96,4x
Nbr of Employees 12
Free-Float 72,3%
Chart ARIX BIOSCIENCE PLC
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 174,00 GBX
Average target price 221,50 GBX
Spread / Average Target 27,3%
EPS Revisions
Managers and Directors
Robert William Henry Lyne CEO, COO, Secretary, Director & General Counsel
Christian Schetter Managing Director
Marcus Karia Group Finance Director
Peregrine D. E. M. Moncreiffe Non-Executive Chairman
Graeme Smith Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
ARIX BIOSCIENCE PLC-20.55%309
INVESTOR AB (PUBL)44.40%70 889
CK HUTCHISON HOLDINGS LIMITED6.01%30 519
AB INDUSTRIVÄRDEN (PUBL)25.46%16 599
HAL TRUST29.70%14 468
KINNEVIK AB81.61%11 032